Cepheid, Oxford Nanopore Expand Partnership, Revvity Launches New Platform, More

Cepheid and Oxford Nanopore Technologies announced an expansion of their partnership to develop a workflow for rapid bacterial and fungal pathogen identification. The companies are advancing to the next phase of development, building on a promising beta solution already in use by researchers. In this next phase, the updated workflow will enable pathogen identification, antimicrobial resistance profiling, and genomic antibiotic susceptibility testing predictions for bloodstream infection and sepsis research. Press release. 

Scientists have achieved a world first by loading a complete genome onto a quantum computer. The breakthrough comes from a collaboration between the Wellcome Sanger Institute and the Universities of Oxford, Cambridge, and Melbourne, with Kyiv Academic University. The genome was loaded onto an IBM quantum computer, powered by the company’s latest 156-qubit Heron processor. The team successfully completed the milestone as part of the Quantum for Bio (Q4Bio) Challenge, a competitive and international research program funded by Wellcome Leap. The challenge aims to accelerate the applications of quantum computing in human health, which may pave the way for faster tracking of infectious disease, deepen understanding of genetic disorders, and more accurately identify disease-causing mutations. Press release. 

bioMérieux announced the launch of BIOFIRE SPOTFIRE for pharmaceutical industries. BIOFIRE SPOTFIRE introduces a simple approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients. The BIOFIRE SPOTFIRE platform is designed to improve operational efficiency and safeguards manufacturing processes. Its automated workflows, intuitive touchscreen interface, and integrated barcode scanning are meant to minimize manual steps, reduce human error, and help ensure secure, traceable data. Press release. 

Revvity announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration. Press release. 

PathAI and MedStar Health have entered a multi-year strategic collaboration to deploy PathAI’s AISight Dx1 Digital Pathology Platform and various AI algorithm products. AISight Dx is PathAI’s cloud native digital pathology image management system designed to support laboratory workflows, clinical operations, and research initiatives. It combines enterprise scale slide management, viewing, and collaboration with seamless AI integration to drive enhanced efficiency and improve speed and consistency. MedStar Health will also deploy algorithms, including ArtifactDetect and TumorDetect2, to further transform pathology workflows across their network of laboratories supporting over 40 pathologists. Press release. 

AAX Biotech entered a partnership with evitria AG to enable the use of its Opti-mAb technology in early antibody development workflows. Through the partnership, evitria will offer its customers access to Opti-mAb technology in the design and optimization stages of antibody candidate development across the biotech and pharmaceutical industries. evitria will also provide access to Opti-mAb under a research license and may incorporate the technology into multispecific antibody formats during early-stage evaluation, based on customer needs and project requirements. Press release. 

Vizgen announced a series of enhancements for the MERSCOPE and MERSCOPE Ultra Platforms to accelerate end-to-end spatial transcriptomics workflows, ensure flexible, high-accuracy segmentation, and deliver high-performance data using state-of-the-art AI models. The new innovations include an expanded line-up of Pre-designed Panels, new Add-on Panel capabilities for customizing content, and AI-powered cell segmentation options offered within the Vizgen Post-processing Tool. Press release. 

TriNetX acquired the key assets of Zetta Genomics. The acquisition expands TriNetX's genomics data management and analytics capabilities, supporting federated capture of multiomic data. This accelerates healthcare providers' ability to integrate phenotypic and multiomic data for improved care delivery and clinical research and enhances the ability of TriNetX's life science customers to perform large-data research in a cost-effective manner. Press release. 

OneCyte and Kemp Proteins have entered a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. This collaboration brings together OneCyte's proprietary single-cell platform for high-throughput, high-sensitivity, and high-speed clone selection with Kemp Proteins' advanced molecular engineering capabilities, including its proprietary machine learning–driven platform, PROTiQ. The companies aim to enable faster development timelines, higher titers, and successful expression of complex and difficult-to-express biologics, including non-monoclonal antibody formats and emerging modalities. Press release. 

Thermo Fisher Scientific launched the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing. The CTS Compleo system offers a compact, automated, functionally closed solution for formulation and filling, helping reduce manual intervention, and supporting consistent batch-to-batch performance. Press release. 

Thermo Fisher Scientific also announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region’s most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for application in earlier detection, prevention, and personalized care. Press release. 

NJ Bio and Aji Bio‑Pharma announced a research collaboration to expand access to AJICAP, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients. Through the collaboration, NJ Bio will integrate the AJICAP platform into its discovery and development workflows, offering clients a highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. Press release. 

The Department of Genetic & Cellular Medicine at UMass Chan Medical School, Caring Cross, and Trenchant BioSystems announced a collaborative research alliance for the development and manufacturing of an accessible and commercially viable hematopoietic stem cell manufacturing platform for diseases such as Sickle Cell Disease. The alliance combines Trenchant BioSystems’ technology for automating patient-specific CGT processes, UMass Chan’s expertise on blood stem cell processes, and Caring Cross’s expertise in increasing patient access. Press release. 

Lonza launched its Media Development Lab at its Singapore site. The offer aims to support bioprocessing customers in optimizing their media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale-up risk, and strengthening long-term supply readiness. Leveraging Design of Experiments, the service evaluates multiple variables simultaneously identifying key performance drivers, accelerating development timelines, and reducing unnecessary iterations. Press release. 

Digital Science has acquired Ontopic. Ontopic’s core technology and flagship product, Ontopic Studio, will be integrated with metaphactory, Digital Science’s industry-leading knowledge democratization platform. This integration will enable users to build and access Knowledge Graphs directly from their existing data sources, without the need for expensive and time-consuming data transformation. By combining Ontopic’s virtualization capabilities with metaphactory’s low-code environment for semantic modeling and discovery, Digital Science is creating a seamless, end-to-end pipeline for the “Knowledge-First” enterprise. Press release.